Severity: 8192
Message: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated
Filename: helpers/my_audit_helper.php
Line Number: 8900
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 8900
Function: str_replace
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3362
Function: formatAIDetailSummary
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Background: Diagnostic accuracy of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) in identification of intracranial abnormalities detected by computed tomography (CT) in mild traumatic brain injury (mTBI), and in patients with mild neurological symptoms not caused by head trauma but suspected with a neurological disorder, was examined.
Methods: GFAP and UCH-L1 were determined using the chemiluminescence immunoassays on the Alinity i analyzer (Abbott Laboratories).
Results: Significantly higher GFAP (median 53.8 vs 25.7 ng/L, P < .001) and UCH-L1 (median 350.9 vs 153.9 ng/L, P < .001) were found in mTBI compared to non-head trauma patients. In mTBI diagnostic sensitivity (Se) and specificity (Sp) for the combination of GFAP and UCH-L1 were 100% and 30.9%, respectively, with area under the curve (AUC) 0.655. GFAP alone yielded Se 85.7%, Sp 41.8%, and AUC 0.638, while UCH-L1 yielded Se 57.1%, Sp 56.4%, and AUC 0.568. In non-head trauma patients, the combination of GFAP and UCH-L1 showed Se 100%, Sp 87.9%, and AUC 0.939, while GFAP alone demonstrated Se 100%, Sp 90.9%, and AUC 0.955.
Conclusions: If these results are reproduced on a larger sample, GFAP and UCH-L1 may reduce CT use in patients with mild neurological symptoms after systemic causes exclusion and neurologist's evaluation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/labmed/lmad116 | DOI Listing |
Am J Emerg Med
December 2024
Warfighter Readiness, Performance, and Brain Health Project Management Office (WRPBH PMO), US Army Medical Materiel Development Activity (USAMMDA), 1430 Veterans Drive, Fort Detrick, MD 21702, USA.
Background: A glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) blood biomarker panel can reliably eliminate the need to perform a head computed tomography (CT) scan in selected patients with traumatic brain injury (TBI). Currently, this FDA cleared panel can be run both on a core laboratory platform or a hand-held single-sample point of care platform. This study examined test characteristics of the panel as analyzed on a core lab-based fast high-throughput platform.
View Article and Find Full Text PDFJ Infect Dis
December 2024
Department of Infection Biology, London School of Hygiene and Tropical Medicine, United Kingdom.
Background: Malaria remains a major public health concern with substantial morbidity and mortality worldwide. In Malaysia, the emergence of Plasmodium knowlesi has led to a surge in zoonotic malaria cases and deaths in recent years. Signs of cerebral involvement have been observed in a noncomatose, fatal case of knowlesi infection, but the potential impact of this malaria species on the brain remains unexplored.
View Article and Find Full Text PDFInt J Technol Assess Health Care
December 2024
Neurology
January 2025
From the Perioperative, Acute, Critical Care and Emergency Medicine (PACE) (D.P.W., D.M., V.F.J.N.), Department of Medicine, University of Cambridge, Addenbrooke's Hospital; Division of Psychology (L.W.), University of Stirling, United Kingdom; Department of Neurosurgery (E.C.), Medical School, and Neurotrauma Research Group (E.C.), Szentagothai Research Centre, University of Pecs, Hungary; Department of Neurosurgery (A.B.), Faculty of Medicine and Health, Örebro University, Sweden; Department of Neurobiology (K.K.W.W.), Center for Neurotrauma, Multiomics & Biomarkers (CNMB) Neuroscience Institute, Morehouse School of Medicine (MSM), Atlanta, GA; Program for Neurotrauma, Neuroproteomics and Biomarker Research (K.K.W.W.), Departments of Emergency Medicine, Psychiatry and Neuroscience, University of Florida, McKnight Brain Institute, Gainesville; Institute of Psychology (N.v.S., M.Z.), University of Innsbruck; Faculty of Psychotherapy Science (M.Z.), Sigmund Freud University, Vienna, Austria; Department of Biomedical Data Sciences (E.S.), Leiden University Medical Center, the Netherlands; Department of Neurosurgery (A.I.R.M.), Antwerp University Hospital, Edegem; and Department of Translational Neuroscience (A.I.R.M.), Faculty of Medicine and Health Science, University of Antwerp, Belgium.
Background And Objectives: There is seemingly contradictory evidence concerning relationships between day-of-injury biomarkers and outcomes after mild traumatic brain injury (mTBI). To address this issue, we examined the association between a panel of biomarkers and multidimensional TBI outcomes.
Methods: Participants with mTBI (Glasgow coma scores [GCSs] 13-15) were selected from Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury, a European observational study recruiting patients with TBI with indication for brain CT and presentation within 24 hours.
Stroke
January 2025
Stroke Center, Department of Neurology (Z.-N.G., Y.Q., R.A., H.J., P.Z., J.W., K.-J.Z., S.Q., X.S., Y.Y.), The First Hospital of Jilin University, Changchun, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!